Streetbeat News

Stock Prices

ALNY

Over the past 15 years, Alnylam Pharmaceuticals (NASDAQ:ALNY) has produced an average annual return of 14.93%, outperforming the market by 1.77% on an annualized basis. With a current market capitalization of $18.95 billion, a $100 investment in ALNY 15 years ago would be worth $761.38 today. This showcases the impact of compounded returns on cash growth over time.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 2:30 pm

META

Wells Fargo analyst Ken Gawrelski maintains an Overweight rating on Meta Platforms (NASDAQ:META) and raises the price target from $536 to $609.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 2:27 pm

AZN

AstraZeneca Plc (NASDAQ:AZN) announced positive results from the DUO-E Phase 3 trial of Imfinzi plus Lynparza in pMMR advanced or recurrent endometrial cancer, showing significant clinical benefits over chemotherapy alone. The combination therapy demonstrated improvements in key secondary efficacy endpoints, including duration of response and reduction in the risk of second progression or death. Additionally, AstraZeneca revealed a new pricing policy for its U.S. inhaled respiratory medicines, capping the cost at $35 per month for eligible patients starting June 1, 2024. AZN shares slightly declined by 0.24% to $66.15.

Portfolio Pulse from Vandana Singh

March 18, 2024 | 2:25 pm

USO

XOM

During a live interview on CNBC, Exxon Mobil's CEO Darren Woods stated that the demand for oil and petroleum products remains very healthy. This indicates a positive outlook for the oil industry, potentially impacting related stocks and ETFs.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 2:22 pm

AMZN

LLY

MRK

NVO

Eli Lilly's Zepbound overtakes Novo Nordisk's Wegovy in new U.S. prescriptions for weight loss, marking a significant milestone since its launch in December. Despite Wegovy's lead in total prescriptions, Zepbound's surge highlights the competitive landscape in the GLP-1 drug market, expected to reach $105 billion by 2029. Additionally, Eli Lilly partners with Amazon Pharmacy for home delivery of select medications, enhancing access to treatments. Eli Lilly also combats counterfeit tirzepatide products through legal action.

Portfolio Pulse from Vandana Singh

March 18, 2024 | 2:21 pm

SHCO

Soho House & Co's stock (SHCO) is experiencing a rebound in trading, potentially recovering from a significant drop last Friday due to disappointing Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 2:19 pm

LEGH

Legacy Housing's stock price declined following the announcement of disappointing Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 2:18 pm

LEGH

Legacy Housing (NASDAQ:LEGH) reported Q4 2023 earnings of $0.34 per share, missing the consensus estimate of $0.77 by 55.84%. Quarterly sales were $33.670M, missing the estimate of $60.648M by 44.48%, and representing a 55.43% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 2:16 pm

BMY

JNJ

LEGN

TSVT

The FDA's ODAC has recommended expanded use of Bristol Myers Squibb & Co and 2seventy bio Inc's Abecma for blood cancer, and Johnson & Johnson/Legend Biotech Corporation's Carvykti, also for blood cancer. Both recommendations are based on positive Phase 3 study results. The FDA is reviewing supplemental Biologics License Applications for both therapies, with decisions pending. Abecma has already received approval in Japan and Switzerland, and a positive opinion in Europe. Competition among CAR-T therapies, including from bispecifics, is noted.

Portfolio Pulse from Vandana Singh

March 18, 2024 | 2:16 pm

BABA

Deep-pocketed investors have shown a bearish sentiment towards Alibaba Group Holding (NYSE:BABA), with a notable shift in options trading activity. Benzinga's tracking revealed 20 extraordinary options activities, with a bearish majority of 60%. The options trading suggests a targeted price range of $65.0 to $80.0 for BABA over the last 3 months. Today's trading showed an average open interest of 10261.2 for Alibaba's options, with a total volume of 5,457.00. Alibaba, the world's largest online and mobile commerce company, saw its stock price slightly up by 0.01% at $73.43.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 2:16 pm